Candida albicans biofilm formation and its clinical consequences

Future Microbiology

Volumn 4, Issue 10, 2009, Pages 1235-1237

  Uppuluri, Priya ^a   Pierce, Christopher G ^a   López Ribot, José Luis ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; RAS PROTEIN;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL RESISTANCE; BIOFILM; CANDIDA ALBICANS; CANDIDIASIS; DEVICE INFECTION; EDITORIAL; FUNGAL COMMUNITY; FUNGAL STRAIN; FUNGAL VIRULENCE; FUNGUS GROWTH; IMMUNE DEFICIENCY; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

BIOFILMS; CANDIDA ALBICANS; CANDIDIASIS; HUMANS;

CANDIDA ALBICANS;

EID: 74749095409     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.09.85     Document Type: Editorial

References (18)

1. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappin-Scott HM: Microbial biofilms. Annu. Rev. Microbiol. 49, 711-745 (1995).
2. Donlan RM: Biofilms: microbial life on surfaces. Emerg. Infect. Dis. 8, 881-890 (2002).
3. Donlan RM: Biofilm formation: a clinically relevant microbiological process. Clin. Infect. Dis. 33, 1387-1392 (2001).
4. Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL: Candida biofilms: an update. Eukaryot. Cell 4, 633-638 (2005).
5. Kojic EM, Darouiche RO: Candida infections of medical devices. Clin. Microbiol. Rev. 17, 255-267 (2004).
6. Ramage G, Martinez JP, Lopez-Ribot JL: Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res. 6, 979-986 (2006).
7. Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20, 133-163 (2007).
8. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB: Nosocomial bloodstream infections in US hospitals: ana lysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39, 309-317 (2004).
9. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA: Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J. Bacteriol. 183, 5385-5394 (2001).
10. Blankenship JR, Mitchell AP: How to build a biofilm: a fungal perspective. Curr. Opin. Microbiol. 9, 588-594 (2006).
11. Nobile CJ, Mitchell AP: Genetics and genomics of Candida albicans biofilm formation. Cell Microbiol. 8, 1382-1391 (2006).
12. Hogan DA, Sundstrom P: The Ras/cAMP/PKA signaling pathway and virulence in Candida albicans. Future Microbiol. 4(10), 1263-1270 (2009).
13. Langford ML, Atkin AL, Nickerson KW: Cellular interactions of farnesol, a quorum-sensing molecule produced by Candida albicans. Future Microbiol. 4(10), 1353-1362 (2009).
14. Ramage G, Van de Walle K, Lopez-Ribot JL, Wickes BL: The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol. Lett. 214, 95-100 (2002).
15. Nobile CJ, Schneider HA, Nett JE et al.: Complementary adhesin function in C. albicans biofilm formation. Curr. Biol. 18, 1017-1024 (2008).
16. Martins M, Henriques M, Azeredo J, Rocha SM, Coimbra MA, Oliveira R: Morphogenesis control in Candida albicans and Candida dubliniensis through signaling molecules produced by planktonic and biofilm cells. Eukaryot. Cell 6, 2429-2436 (2007).
17. Ramage G, Saville SP, Wickes BL, Lopez-Ribot JL: Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl. Environ. Microbiol. 68, 5459-5463 (2002).
18. Bachmann SP, Van de Walle K, Ramage G et al.: In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob. Agents Chemother. 46, 3591-3596 (2002).